Patent application number | Description | Published |
20130242989 | UNREGISTERED MULTICAST (MC) PACKET FORWARDING TO MULTICAST ROUTER PORTS - In one embodiment, a system includes a switching processor, logic configured for installing a Multicast Control (MC) table on a switching processor managing switching on a virtual local area network, logic configured for determining if multicast flooding is disabled in the switching processor, logic configured for installing a drop entry in the MC table upon determining that multicast flooding is disabled in the switching processor, logic configured for detecting whether one or more multicast routers is connected to one or more ports coupled to the switching processor, logic configured for receiving at least one multicast packet, and logic configured for dropping the at least one multicast packet based on the drop entry when no multicast router is connected to any of the one or more ports coupled to the switching processor. Other systems, methods, and computer program products are presented in accordance with more embodiments. | 09-19-2013 |
20130259047 | INTERNET GROUP MEMBERSHIP PROTOCOL GROUP MEMBERSHIP SYNCHRONIZATION IN VIRTUAL LINK AGGREGATION - In one embodiment, a system includes at least one local processor adapted for executing logic, logic adapted for receiving a packet from an access switch on a virtual link aggregation (vLAG) port of a first switch, logic adapted for modifying a source media access control (MAC) address of the packet to include a MAC address of the first switch, wherein a last byte of the modified source MAC address includes a trunk identifier of the vLAG port on which the packet was received, and logic adapted for forwarding the packet to an inter-switch link (ISL) port. Other systems, methods, and computer program products are presented according to more embodiments. | 10-03-2013 |
20140059529 | NON-DISRUPTIVE SOFTWARE UPDATES FOR SERVERS PROCESSING NETWORK TRAFFIC - Updating software on first and second network controller entities (NCEs), without disrupting traffic processing, comprises resetting the second NCE after it receives a proposed software version from the first NCE. The second NCE runs the proposed software version in a standby role. While the second NCE runs the proposed software version in the standby role, databases of the NCEs stay synchronized. Resetting the first NCE induces the second NCE to assume the master role, and the first NCE to assume the standby role. The second NCE in the master role tests the proposed software version for a predetermined period. If validation succeeds, the second NCE instructs the first NCE to reboot and run the proposed software version in the standby role. Otherwise, the second NCE reverts to running the current software version in the standby role; and the first NCE, running the current software version, reverts to the master role. | 02-27-2014 |
20140059530 | NON-DISRUPTIVE SOFTWARE UPDATES FOR SERVERS PROCESSING NETWORK TRAFFIC - Updating software on first and second network controller entities (NCEs), without disrupting traffic processing, comprises resetting the second NCE after it receives a proposed software version from the first NCE. The second NCE runs the proposed software version in a standby role. While the second NCE runs the proposed software version in the standby role, databases of the NCEs stay synchronized. Resetting the first NCE induces the second NCE to assume the master role, and the first NCE to assume the standby role. The second NCE in the master role tests the proposed software version for a predetermined period. If validation succeeds, the second NCE instructs the first NCE to reboot and run the proposed software version in the standby role. Otherwise, the second NCE reverts to running the current software version in the standby role; and the first NCE, running the current software version, reverts to the master role. | 02-27-2014 |
20140204732 | MULTICAST TRAFFIC FORWARDING ON PRUNED INTERFACE - Embodiments of the invention relate to forwarding traffic for link aggregation groups in a system. One embodiment includes a system with a first module that receives a packet and synchronizes a group membership based on the packet. A second module receives the synchronized group membership from the first module and creates link aggregation group (LAG) entries for a primary switch and a secondary. A router receives join requests from the second module for adding a first interface link and a second interface link to the router. A source transmits traffic for the LAG. The second interface link is placed in a pruned state based on a protocol independent multicast (PIM) assert message received from the second module by the primary switch and the secondary switch. The secondary link forwards traffic in the pruned state to an access switch upon the primary link failing. | 07-24-2014 |
20140204938 | MULTICAST ROUTE ENTRY SYNCHRONIZATION - Embodiments of the invention relate to synchronizing multicast route entries in a system. One embodiment includes a system with a first module that synchronizes a group membership and sets a router processing flag based on an interface where a packet is received. A second module receives the router processing flag and information based on the synchronized group membership from the first module and creates multicast route entries based on processing the information and the router processing flag even on a non-designated router (DR) interface. | 07-24-2014 |
20140269683 | Synchronization of OpenFlow controller devices via OpenFlow switching devices - An OpenFlow switching device of an OpenFlow network sends a message including a flow rule received from a first OpenFlow controller device currently active within the OpenFlow network to a second OpenFlow controller device also currently active within the OpenFlow network. As such, the second OpenFlow controller device stays in synchronization with the first OpenFlow controller device. Upon a third OpenFlow controller device becoming newly active within the OpenFlow network, the OpenFlow switching device sends a message including flow rules of the switching device's flow table to the third OpenFlow controller device. As such, the third OpenFlow controller device becomes immediately up-to-date with respect to this flow table. | 09-18-2014 |
20150016454 | UNREGISTERED MULTICAST PACKET FORWARDING TO MULTICAST ROUTER PORTS - A system includes a switching processor and switching logic. The switching processor is communicatively coupled to a virtual local area network (VLAN) and/or one or more ports. The switching logic is configured to: install a Multicast Control (MC) table on the switching processor, determine if multicast flooding is disabled in the switching processor; detect whether multicast routers are communicatively coupled to the port(s); install a multicast router flood entry on the MC table at least partially in response to detecting that at least one of the multicast routers is communicatively coupled to the port(s); receive at least one multicast packet at the switching processor; determine at least one received multicast packet destination based at least in part on the multicast router flood entry; and send at least one received multicast packet to the destination(s). Exemplary computer program products and methods are also disclosed. | 01-15-2015 |
20150055662 | INTERNET GROUP MANAGEMENT PROTOCOL (IGMP) LEAVE MESSAGE PROCESSING SYNCHRONIZATION - Embodiments relate to synchronizing Internet Group Management Protocol (IGMP) leave processing in a system. One embodiment includes a system with a first access switch, a first virtual switch having a first timer, and a second virtual switch having a second timer. The first virtual switch and the second virtual switch are connected with the first access switch. The first access switch transmits an IGMP leave message to the first virtual switch. The first virtual switch transmits a synchronization message to the second virtual switch. The second virtual switch updates the second timer based on receiving the synchronization message. | 02-26-2015 |
20150063108 | OPENFLOW SWITCH MODE TRANSITION PROCESSING - Embodiments of the invention relate to switch mode transition and processing upon loss of controller communication. One embodiment includes losing a connection with a controller by a switch device, entering a particular mode by the switch device, transferring flow entries of the switch device to one or more tables, and notifying network application protocols that correspond to the transferred flow entries. | 03-05-2015 |
20150109899 | PIM FAST FAILOVER USING PIM GRAFT MESSAGE - A system for PIM fast failover recovery includes a network of a plurality of switching devices. The plurality of switching devices includes a source switching device near a source communicatively connected to a receiver switching device near a receiver by a first interface and at least a third switching device that is communicatively connected to the receiver switching device by a second interface and further is communicatively connected to the source switching device by a third interface. The receiver switching device may discover that the first interface has failed and responds by sending the third switching device a PIM graft message prior to deleting an associated first interface route entry. | 04-23-2015 |
20150117202 | OPENFLOW DATA CHANNEL AND CONTROL CHANNEL SEPARATION - A control channel for routing management messages to or from an OpenFlow controller is separated from a reserved port within a data channel for routing unknown data packets to or from the OpenFlow controller. The port may be reserved by setting a reserved port flag. A packet routing table may include a table miss entry that indicates the unknown packets should be routed via the reserved port. By utilizing the reserved port to route unknown packets, the unknown packets do not traverse into the control channel, and the separation of the OpenFlow control channel from the OpenFlow data channel is enhanced. | 04-30-2015 |
20150138951 | VLAG PIM LINK FAILOVER USING PIM HELLO MESSAGE - A system for PIM vLAG fast link failover recovery includes a first vLAG switch connected to a second vLAG switch by an ISL. The first vLAG switch is connected to an upstream network device by a failed link and the second vLAG switch is connected to the upstream network device by a functional link. To recover from the failed link, the first vLAG switch transmits a ROUTEUPDATE message to the second vLAG switch upon the ISL that instructs the second vLAG switch to receive data traffic from the upstream network device and forward the data traffic to the first vLAG switch upon the ISL. | 05-21-2015 |
20150188722 | VLAG PIM MULTICAST TRAFFIC LOAD BALANCING - A PIM vLAG network load balancing system includes a first vLAG switch and a second vLAG switch each connected to, and receive data traffic from, an upstream network device. The first and second vLAG switches balance network data traffic by both determining a source IP address and a multicast group address associated with the received data traffic, hashing the addresses, combining the hashed addresses to determine a resultant value, and either dropping or transmitting the received data traffic to a downstream network device based upon the resultant value. The first vLAG switch may transmit and the second vLAG switch may drop the received data traffic if the resultant value is a first binary value. The second vLAG switch may transmit and the first vLAG switch may drop the received data traffic if the resultant value is a second binary value. | 07-02-2015 |
20150281072 | LINK AGGREGATION GROUP (LAG) SUPPORT ON A SOFTWARE-DEFINED NETWORK (SDN) - In one embodiment, a system includes a software-defined network (SDN) controller including a processor and logic integrated with and/or executable by the processor, the logic being configured to: receive a port addition indication that a logical port is configured on a switching device, the switching device being connected to the SDN controller and a second device, wherein the logical port represents a link aggregation group (LAG) that includes at least two links between the switching device and the second device, and derive and maintain a logical index for all logical ports in software-defined switching devices connected to the SDN controller based on logical port identifiers thereof. | 10-01-2015 |
Patent application number | Description | Published |
20110152525 | PROCESS FOR PREPARING AMINES FROM ALCOHOLS AND AMMONIA - The present invention provides novel ruthenium based catalysts, and a process for preparing amines, by reacting a primary alcohol and ammonia in the presence of such catalysts, to generate the amine and water. According to the process of the invention, primary alcohols react directly with ammonia to produce primary amines and water in high yields and high turnover numbers. This reaction is catalyzed by novel ruthenium complexes, which are preferably composed of quinolinyl or acridinyl based pincer ligands. | 06-23-2011 |
20120253042 | USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES - A process for preparing amides by reacting a primary amine and a primary alcohol in the presence of a Ruthenium complex to generate the amide and molecular hydrogen. Primary amines are directly acylated by equimolar amounts of alcohols to produce amides and molecular hydrogen (the only byproduct) in high yields and high turnover numbers. Also disclosed are processes for hydrogenation of amides to alcohols and amines; hydrogenation of organic carbonates to alcohols; hydrogenation of carbamates or urea derivatives to alcohols and amines; amidation of esters; acylation of alcohols using esters; coupling of alcohols with water and a base to form carboxylic acids; dehydrogenation of beta-amino alcohols to form pyrazines and cyclic dipeptides; and dehydrogenation of secondary alcohols to ketones. These reactions are catalyzed by a Ruthenium complex which is based on a dearomatized PNN-type ligand of formula A1 or precursors thereof of formulae A2 or A3. | 10-04-2012 |
20130281664 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF - The present invention relates to novel Ruthenium catalysts and related borohydride complexes, and the use of such catalysts, inter alia, for (1) hydrogenation of amides (including polyamides) to alcohols and amines; (2) preparing amides from alcohols with amines (including the preparation of polyamides (e.g., polypeptides) by reacting dialcohols and diamines and/or by polymerization of amino alcohols); (3) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones) or cyclic di-esters (di-lactones) or polyesters); (4) hydrogenation of organic carbonates (including polycarbonates) to alcohols and hydrogenation of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (5) dehydrogenative coupling of alcohols to esters; (6) hydrogenation of secondary alcohols to ketones; (7) amidation of esters (i.e., synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water to form carboxylic acids; and (10) dehydrogenation of beta-amino alcohols to form pyrazines. The present invention further relates to the novel uses of certain pyridine Ruthenium catalysts. | 10-24-2013 |
20140046065 | PROCESS FOR PREPARING AMINES FROM ALCOHOLS AND AMMONIA - The present invention provides novel ruthenium based catalysts, and a process for preparing amines, by reacting a primary alcohol and ammonia in the presence of such catalysts, to generate the amine and water. According to the process of the invention, primary alcohols react directly with ammonia to produce primary amines and water in high yields and high turnover numbers. This reaction is catalyzed by novel ruthenium complexes, which are preferably composed of quinolinyl or acridinyl based pincer ligands. | 02-13-2014 |
20140288306 | PROCESS FOR PREPARING AMINES FROM ALCOHOLS AND AMMONIA - The present invention provides novel ruthenium based catalysts, and a process for preparing amines, by reacting a primary alcohol and ammonia in the presence of such catalysts, to generate the amine and water. According to the process of the invention, primary alcohols react directly with ammonia to produce primary amines and water in high yields and high turnover numbers. This reaction is catalyzed by novel ruthenium complexes, which are preferably composed of quinolinyl or acridinyl based pincer ligands. | 09-25-2014 |
20150284417 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF - The present invention relates to novel Ruthenium complexes and related borohydride complexes, and their use for (1) hydrogenation of amides (including polyamides) to alcohols and amines; (2) preparing amides from alcohols with amines (including preparing polyamides (e.g., polypeptides) by reacting dialcohols and diamines or by polymerization of amino alcohols); (3) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones), cyclic di-esters (di-lactones) or polyesters); (4) hydrogenation of organic carbonates (including polycarbonates) to alcohols and of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (5) dehydrogenative coupling of alcohols to esters; (6) hydrogenation of secondary alcohols to ketones; (7) amidation of esters (synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water to form carboxylic acids; and (10) dehydrogenation of beta-amino alcohols to form pyrazines. The present invention further relates to novel uses of certain pyridine Ruthenium complexes. | 10-08-2015 |
Patent application number | Description | Published |
20110312927 | Progesterone Containing Oral Dosage Forms and Related Methods - The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10 | 12-22-2011 |
20110312928 | Progesterone Containing Oral Dosage Forms and Related Methods - The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10−6 hr/mL:1. | 12-22-2011 |
20120135074 | High-Strength Testosterone Undecanoate Compositions - The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the present invention provides for a pharmaceutical composition that includes a therapeutically effective amount of testosterone undecanoate and a solubilizer. The testosterone undecanoate is solubilized in the composition and is present in an amount such that it comprises about 14 wt % to about 35 wt % of the total composition. | 05-31-2012 |
20120148675 | TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier. | 06-14-2012 |
20120244215 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C | 09-27-2012 |
20130029947 | PROGESTERONE CONTAINING ORAL DOSAGE FORMS AND KITS - The present invention provides for progesterone containing pharmaceutical oral dosage forms, pharmaceutical kits, and related methods. In one embodiment, an oral dosage form formulated for on-going administration is provided. The oral dosage form includes an amount of progesterone and a pharmaceutically acceptable carrier. The oral dosage form is formulated such that upon single dose administration to a non-pregnant woman in follicular phase, the oral dosage form provides a serum progesterone C | 01-31-2013 |
20130029957 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 01-31-2013 |
20130172381 | ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER - The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4×10 | 07-04-2013 |
20130225544 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure | 08-29-2013 |
20140179728 | ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER - The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4×10 | 06-26-2014 |
20140179729 | ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER - The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4×10 | 06-26-2014 |
20140288039 | LIPOBALANCED LONG CHAIN TESTOSTERONE PRODRUGS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select lipobalanced testosterone prodrugs and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a lipobalanced testosterone prodrugs and a pharmaceutically acceptable carrier. | 09-25-2014 |
20140303132 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure | 10-09-2014 |
20140323452 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure | 10-30-2014 |
20140323453 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure | 10-30-2014 |
20150018324 | TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier. | 01-15-2015 |
20150038475 | TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier. | 02-05-2015 |
20150320686 | ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER - The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4×10 | 11-12-2015 |
20150320765 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C | 11-12-2015 |
20150320768 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 11-12-2015 |